News
ESALF
31.50
NaN%
--
Weekly Report: what happened at ESALF last week (1019-1023)?
Weekly Report · 1d ago
Weekly Report: what happened at ESALF last week (1012-1016)?
Weekly Report · 10/19 10:13
Catalyst Watch: Meta earnings, Kroger event, and Black Monday turns 39
Seeking Alpha · 10/16 19:00
Weekly Report: what happened at ESALF last week (1005-1009)?
Weekly Report · 10/12 10:18
Adlai Nortye Group: Only For The Risk-Tolerant After A Massive Rally
Seeking Alpha · 10/08 15:45
Weekly Report: what happened at ESALF last week (0928-1002)?
Weekly Report · 10/05 10:17
Weekly Report: what happened at ESALF last week (0921-0925)?
Weekly Report · 09/28 10:13
Merck Welireg, Eisai Lenvima combo approved for kidney cancer
Seeking Alpha · 09/24 20:32
Weekly Report: what happened at ESALF last week (0914-0918)?
Weekly Report · 09/21 10:13
Nuvation Bio rises on FDA label update for Ibtrozi
Seeking Alpha · 09/17 12:32
Weekly Report: what happened at ESALF last week (0907-0911)?
Weekly Report · 09/14 10:18
Weekly Report: what happened at ESALF last week (0831-0904)?
Weekly Report · 09/07 10:11
Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results
TipRanks · 09/03 16:30
Weekly Report: what happened at ESALF last week (0824-0828)?
Weekly Report · 08/31 10:18
GSK: Still One Of My Top Healthcare Picks
Seeking Alpha · 08/27 12:08
Weekly Report: what happened at ESALF last week (0817-0821)?
Weekly Report · 08/24 10:19
Eisai’s E2086 Metabolism Study Clears a Key Early Milestone for Investors
TipRanks · 08/21 16:31
Lenvatinib Combo Falls Short in Esophageal Cancer: What Eisai Investors Need to Know
TipRanks · 08/21 16:30
Weekly Report: what happened at ESALF last week (0810-0814)?
Weekly Report · 08/17 10:20
Eisai’s E2086 Drug-Interaction Study Sets Up Long-Term Pipeline Potential
TipRanks · 08/14 16:30
More
Webull provides a variety of real-time ESALF stock news. You can receive the latest news about Eisai Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ESALF
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.